Home Overview Press Room Blog Publications For Students about us
Search

About Stem Cell Research


Stem cells are undifferentiated cells that can develop into specialized tissue types. Researchers are investigating how to isolate and culture them, and control their differentiation, in the hope that they can be used to treat and understand a variety of diseases.

Stem cells can be derived from a number of cellular sources: adult, fetal, and placental tissues; umbilical cord blood; and embryos. Stem cells from these different sources have different properties.

Adult stem cells can be obtained from the bodies of adults and children, and until recently considered multipotent, which means that particular adult stem cells can develop into specific tissue types. Adult stem cells have been used in therapies such as bone marrow transplants for years.

Embryonic stem cells are found in early embryos. They are pluripotent, which means they can develop into all tissue types and be cultured as stem cell "lines." No therapies have been developed from human embryonic stem cells, which were first isolated in 1998.

In recent years, new methods of cellular reprogramming have enabled the derivation of so-called induced pluripitent stem (iPS) cells, which seem to have the full powers of embryonic stem cells but are from adult body cells.

Human embryonic stem cell research is controversial because it destroys embryos. Most investigations use embryos created but not used for in vitro fertilization (IVF) treatment. Some scientists have worked to derive human embryonic stem cells using a cloning technique called research cloning, which raises a separate set of troubling questions.



The $3 Billion Question: Kids, Scientists and CIRM[Opinion]by David JensenThe California Stem Cell ReportAugust 22nd, 2010Given the shortage of cash, should California fund stem stem research or schools?
Stem Cell Education and Hypeby Pete ShanksBiopolitical TimesAugust 4th, 2010The embryonic stem cell lobby seems to be making a concerted effort to promote their technology.
FDA approves Geron's groundbreaking study of embryonic cellsby Steve JohnsonMercury NewsJuly 30th, 2010A Menlo Park biotech firm said Friday that federal regulators will let it proceed with the world's first human test of a treatment made from embryonic stem cells, a much-anticipated but controversial study of patients with spinal cord injuries that had been placed on hold for nearly a year because of safety concerns.
Prop 71 mastermind proposes another ballot measureby Jesse ReynoldsBiopolitical TimesJuly 13th, 2010The primary force behind the California stem cell agency asserts that the public should give it even more funds.
Medicine agency stays immune to budget cuts[Quotes CGS's Jesse Reynolds]by Katie WorthSan Francisco ExaminerJuly 11th, 2010The California Institute for Regenerative Medicine has not faced the budget cuts other programs in California have encountered.
Universities Bank on Stem-Cell Research[Quotes CGS's Jesse Reynolds]by Robert A. GuthWall Street JournalJuly 1st, 2010Bay Area universities and research groups are betting they can spawn a new generation of medical breakthroughs and the next growth engine for the region's biotechnology industry.
California stem cell agency bars public from meeting on eggsby Jesse ReynoldsBiopolitical TimesJune 23rd, 2010The CIRM can ill afford to be perceived as closed to public participation.
Bending the Rules in Californiaby Jesse ReynoldsBiopolitical TimesJune 16th, 2010Susanne Schultz recently investigated two organizations which may be skirting California's laws prohibiting payments to women to provide eggs for stem cell research.
Stem cells, human genes, and patentsby Jesse ReynoldsBiopolitical TimesMay 14th, 2010A recent ruling on a stem cell patent is similar with concurrent challenges to patents on human genes related to breast cancer.
PTO Finds Stem Cell Patent Anticipated, Obvious in Light of 'Significant Guideposts'[Quotes CGS's Jesse Reynolds]by Tony Dutra and Joyce CutlerThe Bureau of National AffairsMay 12th, 2010The Patent and Trademark Office appeals board found that a patent on human embryonic stem cells was invalid as obvious at the time of invention.
Displaying 1-10 of 934  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.625.0819 • (F) 1.510.665.8760